

QUICK FACTS:

Company Founded:	1981
Corporate Headquarters:	Danvers, Massachusetts
European Division:	Aachen, Germany
CEO, Chairman and President:	Michael R. Minogue
Number of Employees:	1,000
NASDAQ:	ABMD



Manufactures Impella®, the world's smallest heart pump.



Developed AbioCor™, the First Total Artificial Heart.

OUR PRODUCTS

As an organization, we strive to offer healthcare professionals a wide array of choices across a broad clinical spectrum.

- Impella is the world's smallest heart pump, smaller than the width of a pencil.
- The Impella portfolio (Impella 2.5®, Impella CP®, Impella 5.0®, Impella LD® and Impella RP®) has supported over 50,000 patients in the United States.
- Impella devices offer the unique ability to restore the heart's ability to pump enough blood to the body and move the blood through the heart effectively, enabling the muscle time to rest and potentially recover the heart's native function.
- Pumps in the Impella platform can deliver 2.5 to 5 liters of blood flow per minute.
- Impella devices are inserted via a standard catheterization and assist the heart, allowing it time to rest and recover and restore blood flow to vital organs.

IMPELLA® IN PROTECTED PCI

- Protected PCI procedures are often performed on patients who are told they have no other options to treat their heart failure.
- Impella devices can be used in minimally-invasive Protected PCI (percutaneous coronary intervention) procedures to allow the heart to rest while physicians safely place stents to unblock arteries and encourage blood flow.
- Protected PCI procedures may allow for recovery of the patient's native heart, which is the ideal option for a patient's quality of life.
- The Impella 2.5 and Impella CP are the only FDA-approved percutaneous hemodynamic support devices determined to be safe and effective for the treatment of certain elective and urgent high risk patients.
- The Impella 2.5 heart pump received FDA Premarket Approval (PMA) for high risk PCI in March 2015, and the Impella CP received FDA approval for high risk PCI in December 2016.

IMPELLA® IN CARDIOGENIC SHOCK

- Cardiogenic shock typically occurs during or after a heart attack, when the heart suddenly cannot pump enough blood and oxygen to the body's vital organs.
- Impella is the only minimally-invasive heart pump determined safe and effective to treat cardiogenic shock.
- Ultimately, Impella use in cardiogenic shock can allow the patient to recover with their native heart intact, an ideal option for a patient's quality of life.
- Impella 2.5, Impella CP and Impella 5.0 heart pumps received FDA PMA for the treatment of patients experiencing cardiogenic shock following an acute myocardial infarction/heart attack or after heart surgery in April 2016.

More information about Impella devices can be found on Abiomed.com/Impella